Hwasun Jeonnam National University Hospital Proves 'Top Domestic Level' in Colon and Lung Cancer Treatment Capabilities

HIRA Evaluation Grade 1

[Asia Economy Honam Reporting Headquarters Reporter Yoon Jamin] The colorectal cancer and lung cancer treatment capabilities of Hwasun Chonnam National University Hospital (Director Shin Myung-geun) have been recognized as the best in the country.

Hwasun Chonnam National University Hospital announced on the 12th that it received the highest grade, Grade 1, in the recent "Colorectal Cancer and Lung Cancer Treatment Appropriateness Evaluation" conducted by the Health Insurance Review and Assessment Service (HIRA) for medical institutions nationwide.

Colorectal cancer has received the highest grade consecutively in all seven evaluations so far, and lung cancer has received the highest grade consecutively in all five evaluations.

In this evaluation, Hwasun Chonnam National University Hospital scored 99.87 points for colorectal cancer (national average 97.11 points) and 99.61 points for lung cancer (national average 99.30 points), achieving near-perfect scores.

This evaluation was conducted based on treatment records of patients aged 18 and older who received treatment for each cancer type from January to December 2018.

The main evaluation indicators include the presence of specialized cancer treatment physicians, appropriateness of treatments such as pre- and post-surgery, radiation therapy, chemotherapy, and the length of hospital stay.

Hwasun Chonnam National University Hospital also demonstrated excellent cancer treatment capabilities by receiving a perfect score for stomach cancer and nearly perfect for breast cancer in the "Breast Cancer and Stomach Cancer Appropriateness Evaluation" announced by HIRA last year.

Director Shin Myung-geun of Hwasun Chonnam National University Hospital said, "Unlike the metropolitan area, we are gaining nationwide attention as a differentiated cancer-specialized hospital located in a pristine natural environment. In addition to our excellent cancer treatment competitiveness, we will lead precision medicine such as patient-tailored cancer healing and further enhance customer satisfaction."

Meanwhile, HIRA has been providing cancer-related information of high public interest due to high incidence and mortality rates and evaluating medical quality by announcing annual "appropriateness evaluations" starting with colorectal cancer from the 2011 treatment data, followed by breast cancer (2012), lung cancer (2013), and stomach cancer (2014). Since last year, the evaluation results have been announced biennially for two cancer fields.

This content was produced with the assistance of AI translation services.